Greenlight Biosciences
GreenLight Biosciences employs the Unconstrained Metabolism(R) technology platform to produce sustainable chemicals and fuels.
Launch date
Employees
Market cap
-
Enterprise valuation
CAD62m (Public information from May 2023)
Medford Massachusetts (HQ)
Financials
Estimates*
USD | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|
Revenues | 3.0m | <1m | 6.4m | 6.4m |
% growth | - | (68 %) | 564 % | - |
EBITDA | (27.6m) | (50.5m) | (104m) | (154m) |
% EBITDA margin | (921 %) | (5246 %) | (1631 %) | (2409 %) |
Profit | (28.6m) | (53.3m) | (112m) | (167m) |
% profit margin | (955 %) | (5535 %) | (1759 %) | (2617 %) |
R&D budget | 23.5m | 42.9m | 89.8m | 134m |
R&D % of revenue | 783 % | 4456 % | 1407 % | 2096 % |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$7.0m | Series A | ||
$22.0m | Series B | ||
$20.0m Valuation: $60.0m | Series C | ||
$18.0m Valuation: $48.0m | Series D | ||
$50.0m | Late VC | ||
* | $17.0m Valuation: $310m 103.3x EV/LTM Revenues -11.2x EV/LTM EBITDA | Late VC | |
* | $173m Valuation: $1.2b 1247.4x EV/LTM Revenues -23.8x EV/LTM EBITDA | SPAC IPO | |
* | $105m Valuation: $1.2b 1247.4x EV/LTM Revenues -23.8x EV/LTM EBITDA | SPAC Private Placement | |
* | N/A | $109m | Private Placement VC |
* | N/A | $45.5m Valuation: $45.5m 7.1x EV/LTM Revenues -0.3x EV/LTM EBITDA | Acquisition |
Total Funding | CAD475m |
Recent News about Greenlight Biosciences
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.